Ventyx Biosciences (VTYX) notifies Nasdaq of common stock delisting

Rhea-AI Filing Summary

Ventyx Biosciences, Inc. notified the Nasdaq Stock Market LLC of the removal of its Common Stock from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934.

The Nasdaq filing cites compliance with 17 CFR 240.12d2-2 procedures and shows an expiration date of March 31, 2018.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-40928

Issuer:	Ventyx Biosciences, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	12790 El Camino Real
	Suite 222
	San Deigo	CALIFORNIA	92130
Telephone number:					760-407-6511

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-03-04	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did Ventyx Biosciences (VTYX) file Form 25 with Nasdaq?

Form 25 notifies removal of listing/registration. The filing states Nasdaq and the issuer complied with 17 CFR 240.12d2-2 procedures for voluntary withdrawal of the class of securities from listing and registration.

When does the Form 25 filing for Ventyx Biosciences take effect?

The document shows an expiration date of March 31, 2018. The filing text includes that date and indicates the exchange completed the procedural steps under the referenced rules.

What class of securities did Ventyx Biosciences remove from Nasdaq?

The filing covers Ventyx Biosciences' Common Stock. The Form 25 identifies the class as Common Stock and states the exchange struck the class from listing and/or withdrew registration.

Who certified the removal of Ventyx Biosciences' listing on Nasdaq?

Nasdaq Stock Market LLC certified the Form 25. The filing is signed on behalf of Nasdaq by Jennifer Fainer, CDO Analyst, stating Nasdaq has reasonable grounds and complied with the applicable rules.

Where is Ventyx Biosciences' principal executive office as shown in the filing?

The filing lists the address as 12790 El Camino Real, Suite 222, San Diego, California 92130. A telephone number of 760-407-6511 is also provided in the document.